Background and ObjectivesThe purpose of this clinical feasibility trial was to evaluate the preliminary results regarding postoperative outcomes of inferior turbinate reduction using a 1,940-nm thulium laser system.
Materials and MethodsThis clinical feasibility trial included eight patients with inferior turbinate hypertrophy. The inferior turbinate reduction was performed using a 1,940-nm thulium laser with 4.5 W of output power. Intraoperative scoring was performed by a surgeon rating the ablative capacity of the apparatus
ResultsNo complications were observed in this study. The surgeon's mean rating on the ablative capacity of the laser was 4.13 ± 0.35. Postoperative pain decreased prominently (4.13 ± 2.10, 1.38 ± 1.19, 0.25 ± 0.46 on postoperative day one, week one, and week two, respectively) with a statistically significant difference observed between postoperative day one and week two [p=0.0005]. Swelling on postoperative day one had decreased significantly by postoperative week one [p=0.001]. Scar contraction score on postoperative day one had decreased significantly by postoperative week one [p=0.003].
ConclusionThe 1,940-nm Thulium fiber laser system is an efficient alternative to conventional laser systems in the treatment of nasal congestion due to hypertrophied nasal turbinates. Further randomized comparative clinical trials are needed to confirm these results and to extend the 1,940-nm laser-energy application in the clinics.